Research LetterThe effectiveness and safety of mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines among individuals with chronic kidney diseases
Graphical abstract
Section snippets
Results
A total of 144,591 individuals with CKD before the matched first vaccination date were included, and 220 subjects aged below 18 years and 3130 subjects who received different brands of vaccines were excluded (Supplementary Figure S1).
Discussion
Our study demonstrated that both BNT162b2 and CoronaVac were effective against severe outcomes after the COVID-19 infection by reducing hospitalization and mortality and safe with no increased risk of adverse events of special interest observed during the study period. These results are consistent with the findings among the general population in Hong Kong.4
For both BNT162b2 and CoronaVac, the vaccine effectiveness against the infection is substantially lower than the one for more severe
Disclosure
CKHW reports the receipt of General Research Fund, Research Grants Council (RGC), Government of Hong Kong Special Administrative Region (HKSAR) and EuroQol Research Foundation, all outside the submitted work. CSLC has received grants from the Food and Health Bureau of the Hong Kong Government, Hong Kong RGC, Hong Kong Innovation and Technology Commission, Pfizer, IQVIA, and Amgen; and personal fees from Primevigilance Ltd., outside the submitted work. FTTL has been supported by the RGC
Data Statement
Data will not be available for others as the data custodians have not given permission.
Acknowledgments
The authors thank the Hospital Authority and the Department of Health for the generous provision of data for this study and Vincent Yan for technical support. Research grant has been received from The Food and Health Bureau, the Government of Hong Kong Special Administrative Region, China. The funders did not have any role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to
References (9)
- et al.
Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey
Lancet
(2021) Predicting COVID-19 vaccine hesitancy in Hong Kong: vaccine knowledge, risks from coronavirus, and risks and benefits of vaccination
Vaccine X
(2022)- et al.
COVID-19 and chronic kidney disease: an updated overview of reviews
J Nephrol
(2022) Comirnaty and Pfizer-BioNTech COVID-19 Vaccine
Cited by (0)
- 9
FWTC and MF contributed equally to this article and are designated as co-first authors.